MacroGenics, Inc. Class Action: The Gross Law Firm Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 - MGNX

Core Viewpoint - MacroGenics, Inc. (NASDAQ: MGNX) is facing a class action lawsuit due to alleged material misrepresentations regarding the safety data of its drug vobramitamab duocarmazine during the TAMARACK Phase 2 study, leading to a significant stock decline of 77.4% [1][2]. Group 1 - The class period for the lawsuit is defined as March 7, 2024, to May 9, 2024 [1]. - On May 9, 2024, it was revealed that the drug was significantly more dangerous than previously claimed, resulting in a stock price drop of $11.36 per share [1]. - Shareholders are encouraged to register for the class action and can do so without any cost or obligation [2]. Group 2 - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].